250 related articles for article (PubMed ID: 25022450)
1. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Vranceanu AM; Merker VL; Plotkin SR; Park ER
J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
[TBL] [Abstract][Full Text] [Related]
2. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.
Zale EL; Pierre-Louis C; Macklin EA; Riklin E; Vranceanu AM
J Neurooncol; 2018 Apr; 137(2):321-329. PubMed ID: 29275505
[TBL] [Abstract][Full Text] [Related]
3. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
[TBL] [Abstract][Full Text] [Related]
4. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.
Vranceanu AM; Riklin E; Merker VL; Macklin EA; Park ER; Plotkin SR
Neurology; 2016 Aug; 87(8):806-14. PubMed ID: 27449066
[TBL] [Abstract][Full Text] [Related]
5. The development of a patient-centered program based on the relaxation response: the Relaxation Response Resiliency Program (3RP).
Park ER; Traeger L; Vranceanu AM; Scult M; Lerner JA; Benson H; Denninger J; Fricchione GL
Psychosomatics; 2013; 54(2):165-74. PubMed ID: 23352048
[TBL] [Abstract][Full Text] [Related]
6. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
7. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
8. Mind-Body Therapy via Videoconferencing in Patients With Neurofibromatosis: Analyses of 1-Year Follow-up.
Lester EG; Gates MV; Vranceanu AM
Ann Behav Med; 2021 Feb; 55(1):77-81. PubMed ID: 32421171
[TBL] [Abstract][Full Text] [Related]
9. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract][Full Text] [Related]
10. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.
Lester EG; Macklin EA; Plotkin S; Vranceanu AM
J Neurooncol; 2020 Apr; 147(2):451-457. PubMed ID: 32078086
[TBL] [Abstract][Full Text] [Related]
11. Resiliency outcomes after participation in an asynchronous web-based platform for adults with neurofibromatosis: The NF-Web study.
Wang KE; Vranceanu AM; Lester EG
PLoS One; 2023; 18(12):e0295546. PubMed ID: 38127915
[TBL] [Abstract][Full Text] [Related]
12. A Virtual Resiliency Intervention Promoting Resiliency for Parents of Children with Learning and Attentional Disabilities: A Randomized Pilot Trial.
Park ER; Perez GK; Millstein RA; Luberto CM; Traeger L; Proszynski J; Chad-Friedman E; Kuhlthau KA
Matern Child Health J; 2020 Jan; 24(1):39-53. PubMed ID: 31650412
[TBL] [Abstract][Full Text] [Related]
13. The impact of a virtual mind-body program on symptoms of depression and anxiety among international English-speaking adults with neurofibromatosis.
McDermott K; Bakhshaie J; Brewer J; Vranceanu AM
Am J Med Genet A; 2024 Jun; 194(6):e63543. PubMed ID: 38318960
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Blakeley JO; Plotkin SR
Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of adults with neurofibromatosis regarding the design of psychosocial trials: Results from an anonymous online survey.
Wolters PL; Ghriwati NA; Baker M; Martin S; Berg D; Erickson G; Franklin B; Merker VL; Oberlander B; Reeve S; Rohl C; Rosser T; Vranceanu AM
Clin Trials; 2024 Feb; 21(1):73-84. PubMed ID: 37962219
[TBL] [Abstract][Full Text] [Related]
17. Adaptation of a Live Video Mind-Body Program to a Web-Based Platform for English-Speaking Adults With Neurofibromatosis: Protocol for the NF-Web Study.
Lester EG; Hopkins SW; Popok PJ; Vranceanu AM
JMIR Res Protoc; 2021 Jun; 10(6):e27526. PubMed ID: 34110294
[TBL] [Abstract][Full Text] [Related]
18. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
19. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
[TBL] [Abstract][Full Text] [Related]
20. Effects of a mind-body program on symptoms of depression and perceived stress among adults with neurofibromatosis type 2 who are deaf: A live-video randomized controlled trial.
Carter S; Greenberg J; Funes CJ; Macklin EA; Vranceanu AM
Complement Ther Med; 2021 Jan; 56():102581. PubMed ID: 33197677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
